WebJun 20, 2024 · CytoAgents is a biotechnology company focused on the the treatment of COVID-19, Influenza and other viral infectious diseases. Where We Are 100 S … WebAug 10, 2024 · CytoAgents is a privately held, clinical-stage biotechnology company focused on the development of innovative pharmaceutical products for the treatment of …
CytoAgents Announces Appointment of New Chief Medical Officer
WebSep 7, 2024 · CytoAgents is developing innovative pharmaceutical products to treat life-threatening conditions, diseases and disorders associated with Cytokine Release … WebSep 7, 2024 · PITTSBURGH-- ( BUSINESS WIRE )-- CytoAgents, Inc., a clinical-stage therapeutics company developing a safe, effective treatment (CTO1681) for Cytokine Release Syndrome (CRS), today announced that it has strengthened its leadership team with the appointment of Arthur P. Bertolino MD, PhD, MBA, as Chief Medical Officer. Dr. to your eternity latino
CytoAgents Appoints Arthur P. Bertolino MD, PhD, MBA, as Chief …
WebMar 10, 2024 · CytoAgents is a clinical stage biotechnology company focused on the development of innovative pharmaceutical products for the treatment of life-threatening symptoms associated with Cytokine ... WebCytoAgents is a biotechnology company focused on the development of innovative pharmaceutical products for the treatment of COVID-19, Influenza, and other viral infectious diseases. Use the CB Insights Platform to explore CytoAgents's full profile. WebHow CTO1681 Works. CytoAgents’ drug candidate, CTO1681 (formerly GP1681), prevents and treats Cytokine Release Syndrome by targeting the NF-kB signaling pathway and modulating cytokine production, resulting in reduced inflammation. NF-kB plays a critical role in the body’s natural regulation, activation, and differentiation of inflammatory ... to your eternity main character